Factor Xa Concept

subject area of

• 4 Clinical potential of low molecular weight heparins  Academic Article
• A Control Switch for Prothrombinase  Academic Article
• A PoTENtial Antidote  Academic Article
• A Replacement for Warfarin  Academic Article
• A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery  Academic Article
• A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist.  Academic Article
• A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury  Academic Article
• A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)  Academic Article
• A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer  Academic Article
• A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin  Academic Article
• Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and d-Phe-Pro-Arg-Ch2Cl  Academic Article
• Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparin  Academic Article
• Acute management of bleeding in patients on novel oral anticoagulants  Academic Article
• Advances in the management of venous thromboembolism.  Academic Article
• Age-related differences in heparin response  Academic Article
• An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition  Academic Article
• An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice  Conference Paper
• An overview of clinical trials of low molecular weight heparin fractions.  Academic Article
• An overview of the mechanism of action of antithrombin and its inherited deficiency states  Academic Article
• Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors  Academic Article
• Andexanet Alfa for Bleeding with Factor Xa Inhibitors  Academic Article
• Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity  Academic Article
• Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence  Academic Article
• Andexanet alfa for the treatment of hemorrhage  Academic Article
• Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients  Academic Article
• Anticoagulant and Antithrombin Effects of Intimatan, a Heparin Cofactor II Agonist  Academic Article
• Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa  Academic Article
• Apixaban in Acute Coronary Syndromes  Academic Article
• Apixaban in Patients with Atrial Fibrillation  Academic Article
• Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement  Academic Article
• Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome  Academic Article
• Bleeding Complications and Management on anticoagulant therapy  Academic Article
• Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery  Academic Article
• Brief Communication: Preoperative Anticoagulant Activity after Bridging Low-Molecular-Weight Heparin for Temporary Interruption of Warfarin  Academic Article
• Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity  Academic Article
• Chemical–Physical Characterization of Polyurethane Catheters Modified with a Novel Antithrombin-Heparin Covalent Complex  Academic Article
• Clinical implications of reversal agents for direct oral anticoagulants  Academic Article
• Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.  Academic Article
• Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins  Academic Article
• Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)-5 trial  Academic Article
• Covalent antithrombin–heparin complexes  Academic Article
• Covalently linking heparin to antithrombin enhances prothrombinase inhibition on activated platelets  Academic Article
• Dabigatran: ready for prime time?  Academic Article
• Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency  Academic Article
• Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation  Academic Article
• Direct Factor Xa and direct thrombin inhibitors: a clinical trial update.  Academic Article
• Duration of anticoagulant therapy for venous thromboembolism  Academic Article
• Effects of Dermatan Sulfate and Heparin on Inhibition of Thrombus Growth in Vivo  Academic Article
• Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III  Academic Article
• Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli.  Academic Article
• Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction  Academic Article
• Enoxaparin Use in the Neonatal Intensive Care Unit: Experience Over 8 Years  Academic Article
• Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.  Academic Article
• Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor–associated major bleeding  Academic Article
• Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin  Academic Article
• Factor Xa or thrombin: Is thrombin a better target?  Conference Paper
• Fondaparinux Reduces Long-term Risk of Venous Thromboembolism After Surgery for Hip Fractur  Academic Article
• Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6  Academic Article
• Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors  Academic Article
• Further Studies on the Mechanisms for the Antithrombotic Effects of Sulfated Polysaccharides in Rabbits  Academic Article
• Glycosaminoglycans Bind Factor Xa in a Ca2+-Dependent Fashion and Modulate Its Catalytic Activity†  Academic Article
• Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors  Academic Article
• Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.  Academic Article
• Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance  Academic Article
• Heparin Cofactor II and Other Endogenous Factors in the Mediation of the Antithrombotic and Anticoagulant Effects of Heparin and Dermatan Sulfate  Academic Article
• Heparin and Low Molecular Weight Heparins Inhibit Prothrombinase Formation but not its Activity in Plasma  Academic Article
• Heparin and low molecular weight heparins as scaffolds for assembling antithrombin and serine proteases  Academic Article
• Heparin fractions with high and low affinities to antithrombin iii are cleared at different rates  Academic Article
• Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma  Academic Article
• Hirudin causes more bleeding than heparin in a rabbit ear bleeding model  Academic Article
• How can we reverse bleeding in patients on direct oral anticoagulants?  Academic Article
• How to use unfractionated heparin to treat neonatal thrombosis in clinical practice  Academic Article
• Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase  Academic Article
• Immobilization of an antithrombin–heparin complex on gold: Anticoagulant properties and platelet interactions  Academic Article
• In the Presence of Phospholipids, Glycosaminoglycans Potentiate Factor Xa-Mediated Protein C Activation by Modulating Factor Xa Activity†  Academic Article
• In vivo Effects of Low Molecular Weight Heparins on Experimental Thrombosis and Bleeding  Academic Article
• Incorporation of Factor Va into Prothrombinase Is Required for Coordinated Cleavage of Prothrombin by Factor Xa  Academic Article
• Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate  Academic Article
• Inhibition of Fibrin-Bound Thrombin by a Covalent Antithrombin-Heparin Complex  Academic Article
• Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082  Academic Article
• Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex  Academic Article
• Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys  Academic Article
• Laboratory monitoring of low-molecular-weight heparin therapy  Academic Article
• Letter to the editor  Academic Article
• Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial  Academic Article
• Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review  Academic Article
• Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor  Academic Article
• Measurement of factor Xa-antithrombin III in plasma: relationship to prothrombin activation in vivo  Academic Article
• Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex  Academic Article
• Mechanisms Responsible for Catalysis of the Inhibition of Factor Xa or Thrombin by Antithrombin Using a Covalent Antithrombin-Heparin Complex  Academic Article
• Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin  Academic Article
• Meeting the Unmet Needs in Anticoagulant Therapy  Academic Article
• Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency  Academic Article
• Monitoring Unfractionated Heparin (UFH) therapy: Which Anti Factor Xa assay is appropriate?  Academic Article
• Monitoring and reversal of direct oral anticoagulants  Academic Article
• Monitoring the anticoagulant effect after a massive rivaroxaban overdose  Academic Article
• Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation  Academic Article
• NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank  Academic Article
• Neutralization of Enoxaparine-lnduced Bleeding by Protamine Sulfate  Academic Article
• New Antithrombotic Drugs: Potential for Use in Oncology  Academic Article
• New aspects on treatment modalities for thromboembolic episodes  Academic Article
• New oral anticoagulants in atrial fibrillation  Academic Article
• New oral anticoagulants in development  Academic Article
• New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010  Academic Article
• Novel oral anticoagulants and reversal agents: Considerations for clinical development  Academic Article
• Oral Anticoagulant Therapy  Academic Article
• Oral Apixaban for the Treatment of Acute Venous Thromboembolism  Academic Article
• Oral Rivaroxaban for Symptomatic Venous Thromboembolism  Academic Article
• Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis  Academic Article
• Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement  Academic Article
• Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement  Academic Article
• Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases  Academic Article
• PRE‐OPERATIVE FACTOR Xa–TFPI AND POST‐OPERATIVE VENOUS THROMBOSIS  Academic Article
• PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma  Academic Article
• Preclinical differentiation of low molecular weight heparins.  Academic Article
• Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)  Academic Article
• Protein adsorption on polyurethane catheters modified with a novel antithrombin-heparin covalent complex  Academic Article
• Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation  Academic Article
• Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention  Academic Article
• Rationale Behind the Development of Low Molecular Weight Heparin Derivatives  Academic Article
• Recent Advances in Antidotes for Direct Oral Anticoagulants: Their Arrival Is Imminent  Academic Article
• Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins  Academic Article
• Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban  Academic Article
• Response to “Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban”  Academic Article
• Reversal agents for non-vitamin K antagonist oral anticoagulants  Academic Article
• Reversal of Direct Oral Anticoagulants: Current Status and Future Directions  Academic Article
• Reversal of direct oral anticoagulants: a practical approach  Academic Article
• Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study  Academic Article
• Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty  Academic Article
• SR123781A: A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement Surgery  Academic Article
• Serum-induced platelet procoagulant activity: An assay for the characterization of prothrombotic disorders  Academic Article
• Site-directed mutagenesis of the P2 residue of human antithrombin  Academic Article
• The APTT Response of Pregnant Plasma to Unfractionated Heparin  Academic Article
• The Development of New Factor Xa Inhibitors Based on Amide Synthesis  Academic Article
• The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?  Academic Article
• The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations  Academic Article
• The Real Decoy  Academic Article
• The Relationship between Anti-Factor Xa Level and Clinical Outcome in Patients Receiving Enoxaparine Low Molecular Weight Heparin to Prevent Deep Vein Thrombosis after Hip Replacement  Academic Article
• The Relationship of Antiphospholipid Antibodies to Thromboembolic Disease in Systemic Lupus Erythematosus: A Cross-Sectional Study  Academic Article
• The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studiesin vitro  Academic Article
• The haemorrhagic and antithrombotic effects of dermatan sulphate.  Academic Article
• The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate  Academic Article
• The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor  Academic Article
• The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin  Academic Article
• The interaction of fragment 1 of prothrombin with the membrane surface is a prerequisite for optimum expression of factor Va cofactor activity within prothrombinase  Academic Article
• The low molecular weight heparin Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery  Academic Article
• The relationship between ex vivo anti-factor Xa levels and efficacy/safety of low molecular weight heparin.  Academic Article
• The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin  Academic Article
• Thrombolysis by chemically modified coagulation factor Xa  Academic Article
• Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin  Academic Article
• Thrombosis in inherited factor VII deficiency  Academic Article
• Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Anti–Factor Xa Activity  Academic Article
• Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels  Academic Article
• Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa  Academic Article
• Use of selective factor Xa inhibitors in special populations.  Academic Article
• Utility of aPTT in monitoring unfractionated heparin in children  Academic Article
• Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation  Academic Article
• Very severe thrombocytopenia and fragmentation hemolysis mimicking thrombotic thrombocytopenic purpura associated with a giant intracardiac vegetation infected withStaphylococcus epidermidis: Role of monocyte procoagulant activity induced by bacterial supernatant  Academic Article
• Volutrauma activates the clotting cascade in the newborn but not adult rat  Academic Article
• When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH  Academic Article
• Why Is Factor Xa Not a Better Target Than Factor IIa for Therapeutic Inhibition of Coagulation?  Academic Article
• Zn2+Mediates High Affinity Binding of Heparin to the αC Domain of Fibrinogen  Academic Article